Fierce Pharma Asia—FDA oncology czar on China PD-1 rebuff; US Senate's supply chain bill; Insilico's AI targets

Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence, defended the agency's rejection of Eli Lilly and Innovent Biologics' PD-1 inhibitor. The U.S.

Related Keywords

,Richard Pazdur ,China ,Japan ,Pd 1 L1 ,India ,Supply Chain ,Fierce Pharma Asia ,Eli Lilly ,Innovent ,Insilico Medicine ,Sfda Inspection ,Ono Pharmaceutical ,Immuno Oncology ,Icensing ,Oche ,Chugai ,Halozyme Therapeutics ,Subcutaneous Drug Delivery ,Aurobindo Pharma ,M Amp A ,Player ,Werner Baumann ,Sanofi ,Rare Diseases ,Sun Pharmaceutical ,Isk Bioscience ,Artificial Intelligence ,Coherus ,Junshi Biosciences ,Asia ,Fierce Pharma Homepage ,Pharma ,